ProPhase Labs Inc (PRPH) - Total Liabilities
Based on the latest financial reports, ProPhase Labs Inc (PRPH) has total liabilities worth $58.84 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore PRPH long-term investments to assets to see how much of total assets are deployed in long-term investments.
ProPhase Labs Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how ProPhase Labs Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PRPH asset base.
ProPhase Labs Inc Competitors by Total Liabilities
The table below lists competitors of ProPhase Labs Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Altona Rare Earths PLC
LSE:REE
|
UK | GBX1.51 Million |
|
Dianomi PLC
LSE:DNM
|
UK | GBX5.57 Million |
|
ANGLE plc
LSE:AGL
|
UK | GBX6.39 Million |
|
Tanfield Group PLC
LSE:TAN
|
UK | GBX582.00K |
|
Critical Metals Plc
LSE:CRTM
|
UK | GBX1.15 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down ProPhase Labs Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See PRPH net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 8.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ProPhase Labs Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ProPhase Labs Inc (1996–2024)
The table below shows the annual total liabilities of ProPhase Labs Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $55.85 Million | +31.27% |
| 2023-12-31 | $42.54 Million | +77.14% |
| 2022-12-31 | $24.02 Million | -21.68% |
| 2021-12-31 | $30.67 Million | +47.09% |
| 2020-12-31 | $20.85 Million | +1898.95% |
| 2019-12-31 | $1.04 Million | -75.36% |
| 2018-12-31 | $4.23 Million | +294.87% |
| 2017-12-31 | $1.07 Million | -84.33% |
| 2016-12-31 | $6.84 Million | +14.00% |
| 2015-12-31 | $6.00 Million | +12.34% |
| 2014-12-31 | $5.34 Million | +10.72% |
| 2013-12-31 | $4.82 Million | -7.41% |
| 2012-12-31 | $5.21 Million | -33.66% |
| 2011-12-31 | $7.85 Million | -4.64% |
| 2010-12-31 | $8.23 Million | +43.02% |
| 2009-12-31 | $5.76 Million | -12.69% |
| 2008-12-31 | $6.59 Million | -34.16% |
| 2007-12-31 | $10.02 Million | +8.26% |
| 2006-12-31 | $9.25 Million | -12.73% |
| 2005-12-31 | $10.60 Million | +10.75% |
| 2004-12-31 | $9.57 Million | +74.59% |
| 2003-12-31 | $5.48 Million | -15.80% |
| 2002-12-31 | $6.51 Million | +83.16% |
| 2001-12-31 | $3.56 Million | -26.65% |
| 2000-12-31 | $4.85 Million | -31.72% |
| 1999-12-31 | $7.10 Million | +77.50% |
| 1998-12-31 | $4.00 Million | -50.62% |
| 1997-12-31 | $8.10 Million | +3950.00% |
| 1996-12-31 | $200.00K | -- |
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more